Axsome Therapeutics (AXSM) Other Gross PP&E Adjustments (2020 - 2026)
Axsome Therapeutics recorded quarterly Other Gross PP&E Adjustments of -$24.8 million in Q1 2026, down 18.98% quarter-over-quarter from -$20.9 million in Q4 2025, and up 13.54% year-over-year from -$21.9 million in Q1 2025.
Axsome Therapeutics' Other Gross PP&E Adjustments history runs 7 years deep, the most recent figure standing at -$24.8 million for Q1 2026.
- In Q1 2026, Other Gross PP&E Adjustments rose 13.54% year-over-year to -$24.8 million; the TTM figure through Mar 2026 stood at -$24.8 million (up 13.54% YoY), while the FY2025 annual figure was -$20.9 million, down 287.48% from the prior year.
- Other Gross PP&E Adjustments came in at -$24.8 million for Q1 2026 at Axsome Therapeutics, down from -$20.9 million in the prior quarter.
- In the past five years, Other Gross PP&E Adjustments ranged from a high of -$384568.0 in Q3 2022 to a low of -$28.7 million in Q1 2025.
- A 5-year average of -$11.3 million and a median of -$8.7 million in 2023 frame the typical range for Other Gross PP&E Adjustments.
- Across the five-year window, Other Gross PP&E Adjustments jumped 58.94% in 2022 and tumbled 2155.78% in 2023, its largest moves.
- Axsome Therapeutics' Other Gross PP&E Adjustments stood at -$420000.0 in 2022, then slumped by 1512.38% to -$6.8 million in 2023, then increased by 20.51% to -$5.4 million in 2024, then slumped by 287.48% to -$20.9 million in 2025, then slipped by 18.98% to -$24.8 million in 2026.
- According to Business Quant data, Other Gross PP&E Adjustments over the past three periods registered -$24.8 million, -$20.9 million, and -$23.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Axsome Therapeutics | 11.82 Bn | 11.51 Bn | 176.48 Mn | -24.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -24.82 Mn |
| Mar 31, 2026 | -24.82 Mn |
| Dec 31, 2025 | -20.86 Mn |
| Dec 31, 2025 | -20.86 Mn |
| Sep 30, 2025 | -23.26 Mn |
| Sep 30, 2025 | -23.26 Mn |
| Jun 30, 2025 | -25.69 Mn |
| Jun 30, 2025 | -25.69 Mn |
| Mar 31, 2025 | -28.70 Mn |
| Mar 31, 2025 | -28.70 Mn |
| Dec 31, 2024 | -5.38 Mn |
| Dec 31, 2024 | -5.38 Mn |
| Sep 30, 2024 | -7.34 Mn |
| Sep 30, 2024 | -7.34 Mn |
| Jun 30, 2024 | -9.29 Mn |
| Jun 30, 2024 | -9.29 Mn |
| Mar 31, 2024 | -11.21 Mn |
| Mar 31, 2024 | -11.21 Mn |
| Dec 31, 2023 | -6.77 Mn |
| Dec 31, 2023 | -6.77 Mn |
| Sep 30, 2023 | -8.68 Mn |
| Sep 30, 2023 | -8.68 Mn |
| Jun 30, 2023 | -10.63 Mn |
| Jun 30, 2023 | -10.63 Mn |
| Mar 31, 2023 | -6.48 Mn |
| Mar 31, 2023 | -6.48 Mn |
| Dec 31, 2022 | -420,000.00 |
| Dec 31, 2022 | -420,000.00 |
| Sep 30, 2022 | -384,568.00 |
| Sep 30, 2022 | -384,568.00 |
| Jun 30, 2022 | -667,582.00 |
| Jun 30, 2022 | -667,582.00 |
| Mar 31, 2022 | -946,479.00 |
| Mar 31, 2022 | -946,479.00 |
| Dec 31, 2021 | -660,162.00 |
| Dec 31, 2021 | -660,162.00 |
| Sep 30, 2021 | -936,526.00 |
| Sep 30, 2021 | -936,526.00 |
| Jun 30, 2021 | -1.21 Mn |
| Jun 30, 2021 | -1.21 Mn |
| Mar 31, 2021 | -1.48 Mn |
| Mar 31, 2021 | -1.48 Mn |
| Dec 31, 2020 | -1.74 Mn |
| Dec 31, 2020 | -1.74 Mn |